Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ASCENDIS PHARMA A/S - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   5.4% 5.6% 7.0% 5.8% 4.9% 6.4% 4.7% 4.7%   Credit score (0-100)   43 42 34 38 44 36 46 46   Credit rating   BBB BBB BBB BBB BBB BBB BBB BBB   Credit limit (mEUR)   0.0 0.0 0.0 0.0 0.0 -0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mEUR)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   11 13 7 8 51 267 267 267   Gross profit   10.6 13.4 7.0 4.3 39.0 222 0.0 0.0   EBITDA   -155 -227 -331 -452 -562 -456 0.0 0.0   EBIT   -155 -227 -331 -452 -562 -456 0.0 0.0   Pre-tax profit (PTP)   -130.5 -218.3 -419.2 -383.9 -577.8 -474.1 0.0 0.0   Net earnings   -130.1 -218.0 -419.0 -383.6 -583.2 -481.4 0.0 0.0   Pre-tax profit without non-rec. items   -130 -218 -419 -384 -578 -474 0.0 0.0     See the entire income statement 1.0 Balance sheet (mEUR)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   4.3 45.1 108 126 129 111 0.0 0.0   Shareholders equity total   280 597 839 884 263 -146 0.0 0.0   Interest-bearing liabilities   0.0 30.7 0.0 105 399 545 4.4 4.4   Balance sheet total (assets)   319 677 980 1,085 1,090 826 4.4 4.4   Net Debt   -278 -567 -834 -341 -45.6 153 4.4 4.4     See the entire balance sheet 1.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   11 13 7 8 51 267 267 267   Net sales growth   591.6% 26.4% -48.0% 11.9% 557.9% 421.2% 0.0% 0.0%   Gross profit   10.6 13.4 7.0 4.3 39.0 222 0.0 0.0   Gross profit growth   591.6% 26.4% -48.0% -38.8% 817.4% 469.5% -100.0% 0.0%   Employees   0 0 0 573 719 851 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 25.5% 18.4% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   319 677 980 1,085 1,090 826 4 4   Balance sheet change%   51.2% 112.2% 44.8% 10.7% 0.4% -24.2% -99.5% 0.0%   Added value   -154.8 -226.7 -330.6 -451.8 -561.8 -455.5 0.0 0.0   Added value %   -1,462.6% -1,695.1% -4,755.1% -5,808.6% -1,097.9% -170.8% 0.0% 0.0%   Investments   2 41 65 17 3 -19 -111 0   Net sales trend   1.0 2.0 -1.0 1.0 2.0 3.0 0.0 0.0   EBIT trend   -3.0 -4.0 -5.0 -5.0 -5.0 -5.0 0.0 0.0   1.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   -1,462.6% -1,695.1% -4,755.1% -5,808.6% -1,097.9% -170.8% 0.0% 0.0%   EBIT %   -1,462.6% -1,695.1% -4,755.1% -5,808.6% -1,097.9% -170.8% 0.0% 0.0%   EBIT to gross profit (%)   -1,462.6% -1,695.1% -4,755.1% -10,617.9% -1,439.2% -204.9% 0.0% 0.0%   Net Earnings %   -1,229.5% -1,630.0% -6,025.5% -4,931.6% -1,139.6% -180.5% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -1,229.5% -1,630.0% -6,025.5% -4,931.6% -1,139.6% -180.5% 0.0% 0.0%   Pre tax profit less extraordinaries %   -1,233.3% -1,631.8% -6,028.7% -4,936.3% -1,129.1% -177.8% 0.0% 0.0%   ROA %   -49.2% -43.6% -40.8% -36.8% -48.5% -41.7% 0.0% 0.0%   ROI %   -55.8% -47.5% -43.1% -39.5% -54.3% -48.4% 0.0% 0.0%   ROE %   -55.7% -49.7% -58.4% -44.5% -101.7% -88.4% 0.0% 0.0%   1.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   87.8% 88.2% 85.6% 81.4% 24.2% -15.0% 0.0% 0.0%   Relative indebtedness %   367.8% 595.3% 2,029.1% 2,587.9% 1,614.9% 364.2% 1.7% 1.7%   Relative net indebtedness %   -2,258.2% -3,876.5% -9,966.8% -3,149.7% 745.7% 217.1% 1.7% 1.7%   Net int. bear. debt to EBITDA, %   179.5% 250.3% 252.3% 75.5% 8.1% -33.7% 0.0% 0.0%   Gearing %   0.0% 5.1% 0.0% 11.9% 151.6% -374.4% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 7.9% 526.3% 7.5% 20.0% 9.3% 0.0% 0.0%   1.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   7.5 12.7 14.0 7.3 4.6 2.5 0.0 0.0   Current Ratio   7.5 12.7 14.0 8.0 5.4 3.6 0.0 0.0   Cash and cash equivalent   277.9 598.1 834.1 446.3 444.8 392.2 0.0 0.0   1.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.2 21.9 20.3 103.2 84.9 49.1 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   2,768.2% 4,569.5% 10,644.8% 10,361.1% 1,804.6% 263.5% 0.0% 0.0%   Net working capital   254.0 563.2 437.8 705.5 752.2 505.4 -2.2 -2.2   Net working capital %   2,400.4% 4,210.7% 6,296.1% 9,070.8% 1,469.9% 189.5% -0.8% -0.8%   1.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 -1 -1 -1 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 -1 -1 -1 0 0   EBIT / employee   0 0 0 -1 -1 -1 0 0   Net earnings / employee   0 0 0 -1 -1 -1 0 0